A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Exclusion Criteria

• •Have significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination; constituting a risk when taking the Investigational Medical Product (IMP); or interfering with the interpretation of data
• •Have a prior diagnosis of type 1 or type 2 diabetes mellitus
• •Have a history of acute or chronic pancreatitis
• •Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
• •Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, GIP/GLP-1/glucagon receptor agonist, or amylin receptor agonist within 6 months prior to screening
• •Have been treated with prescription and over-the-counter medications, or alternative remedies (including herbal/nutritional supplements), that promote weight loss within 6 months prior to screening
• •Are pregnant or lactating